“…Among the strategies reported in the literature to overcome these difficulties and improve the therapeutic efficacy of anti-TB drugs is to devise modified drug delivery systems (MDDS). Several works in the literature have reported obtaining MDDS for RIF, using the most diverse types of carriers, such as polymeric nanoparticles [ 10 , 11 , 12 ], microemulsions [ 13 ], dendrimers [ 14 , 15 ], hydrogels [ 6 , 16 , 17 ], liposomes [ 18 ], and lipid nanoparticles [ 19 ], among others. Despite being effective, such systems are based on expensive technologies that require the use of improved materials and/or devices.…”